| Literature DB >> 32181259 |
José Bueno-Lledó1, Omar Carreño-Saenz1, Antonio Torregrosa-Gallud1, Salvador Pous-Serrano1.
Abstract
Objectives: Preoperative botulinum toxin type A (BT) and progressive pneumoperitoneum (PPP) are useful tools in the preparation of patients with loss of domain hernias (LODH). The purpose of our retrospective study is to report our experience in the treatment of 100 consecutive patients with LODH, with the combined use of these techniques.Entities:
Keywords: botulinum toxin; incisional hernia; large incisional hernia; preoperative progressive pneumoperitoneum; ventral hernia
Year: 2020 PMID: 32181259 PMCID: PMC7059432 DOI: 10.3389/fsurg.2020.00003
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
Figure 1Volumetric CT images before botulinum toxin and progressive pneumoperitoneum application. Calculation of hernia sac and abdominal cavity volumes and hernia defect diameters.
Figure 2Algorithm of combination of botulinum toxin and progressive pneumoperitoneum in the treatment of large incisional hernias applied in our hospital.
Figure 3Botulinum toxin application under ultrasonographic and electromyographic guidance on the lateral abdominal wall.
Figure 4Comparation of pictures of patients after combined administration of botulinum toxin and progressive pneumoperitoneum and after following hernia repair.
Demographics and characteristics of the patients with LODH.
| Mean age (range) | 59.4 | |
| Male | 41 (44.2) | |
| Female | 59 (55.8) | |
| First abdominal surgery (%) | Umbilical hernia | 19 (19) |
| Colectomy | 17 (17) | |
| Cesarea | 15 (15) | |
| Cholecystectomy | 11 (11) | |
| Trocar hernia | 9 (9) | |
| Renal transplantation | 9 (9) | |
| Hepatic transplantation | 8 (8) | |
| AAA | 6 (6) | |
| Gastric bypass | 6 (6) | |
| Time of evolution since the first surgery in years (range) | 8.5 | |
| Yes | 11 (11) | |
| No | 89 (89) | |
| Grade I | 17 (17) | |
| Grade II | 54 (54) | |
| Grade III | 29 (29) | |
| OBESITY (BMI >30) (%) | 19 (19) | |
| Midline | 82 (82) | |
| Lateral | 18 (18) | |
| Median operative time in min (range) | 223 | |
| Abdominal wall repair technique (%) | Anterior CST | 57 (57) |
| Level | 40 | |
| Level 1+2 | 14 | |
| Level 1+2+bridging | 3 | |
| TAR | 32 (32) | |
| Rives-Stoppa | 11 (11) | |
| Technique associated with prosthetic repair | Abdominoplasty | 11 (11) |
| Colectomy | 4 (4) | |
| Intestinal resection | 5 (5) | |
| Cholecystectomy | 4 (4) | |
| Colostomy | 3 (3) | |
| Reoperation during hospitalization | 8 (wound infection, dehiscence and necrosis) | |
| Length of postoperative hospital stay in days (range) | 9.4 | |
| Average postoperative follow-up in months (range) | 34.5 | |
| Recurrence (%) | 8 (8) | |
PPP, progressive preoperative pneumoperitoneum; BT, botulinum toxin A; SD, standard deviation; AAA, abdominal aortic aneurysm; CST, component separation technique; PVDF, polyvinylidene fluoride; ACS, abdominal compartment syndrome.
Peritoneal volumes and hernia defect diameters before and after preoperative techniques.
| VIH (cc) | 1517 | 2019 | 0.004 |
| VAC (cc) | 9322 | 10910 | 0.011 |
| VIH/VAC ratio (%) | 29.1 | 14.1 | 0.001 |
| Median transverse diameter of hernia defect (cms) | 16.1 | 15.1 | 0.455 |
PPP, progressive preoperative pneumoperitoneum; BT, botulinum toxin A; VIH, incisional hernia volume; VAC, abdominal cavity volume.
Complications associated to the PPP and hernia repair according to the Clavien-Dindo classification.
| Grade I | Shoulder pain 6 (6) | Analgesics | Seroma 10 (10) | No need of surgery |
| Grade III | Intraabdominal hematoma 2 (2) | No need of surgery | Wound necrosis 4 (4) | Surgical debridement (2) |
| Grade IV | Intestinal perforation 1 (1) | No need of surgery | ARDS 2 (2) | Ventilatory support in ICU |
There were no complications during the administration of BT.
PPP, progressive preoperative pneumoperitoneum; ARDS, respiratory distress syndrome; ACS, abdominal compartment syndrome; TAR, transversus abdominis release; NPT, negative pressure therapy; ICU, intensive care Unit; CT, abdominal tomography; PTFE, polytetrafluoroethylene.